Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...
Investor's Business Daily on MSN30m
Here's How Donald Trump Could Shake Up Health Care — And Biotech StocksBiotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with a lot of ...
Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...
The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...
Novo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as ...
Potential antitrust deregulation could foster a more favourable environment for larger M&A deals, though skepticism remains.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback